Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

  • End date
    Oct 1, 2025
  • participants needed
  • sponsor
    National Cancer Institute (NCI)
Updated on 15 September 2021
platelet count
granulocyte colony stimulating factor
bone marrow procedure
colony stimulating factor
neutrophil count
chemotherapy regimen
primary cancer
investigational therapy
investigational treatment
experimental therapy


This study will gain information about a rare disorder called KSHV-associated multicentric Castleman s disease (MCD). KSHV, a virus, causes several kinds of cancer, including some forms of MCD. KSHV stands for the Kaposi s sarcoma herpes virus, also called human herpes virus-8, or HHV-8. Researchers want to understand the biology of KSHV-MCD to identify how this disease causes illness and to find ways to treat it. There is no standard therapy effective for all cases of KSHV-MCD. The disease is often fatal, and about half the people who have it die within 2 years of diagnosis.

Participants ages 18 and older may be eligible for this study. Participation entails more drawing of blood and having repeated tumor biopsies than if patients received treatment in a non-research setting. Researchers would like to learn more about the relationship of KSHV and Castleman s disease symptoms, and they want to obtain at least three biopsies in this study.

There are some side effects of experimental therapy that participants may take for KSHV-MCD. Zidovudine, or Retrovir , is used at a high dose. It is given orally or through a vein, four times daily, for 7 days or longer. Zidovudine can cause nausea, vomiting, decreased bone marrow function, and decreased blood counts. Combined with valganciclovir, or Valcyte , it is likely to be more toxic to bone marrow. Valganciclovir can cause problems with bone marrow function, leading to low blood counts, sterility, and defects in a fetus. Combined with zidovudine, valganciclovir may cause more toxicity to the bone marrow. It is given twice daily for 7 days or longer. Bortezomib, or Velcade , is given for a few seconds by a rapid push through a needle into the vein. It is given twice weekly for four doses and then stopped for 1 week. Bortezomib can sometimes cause low blood pressure; it also can cause gastrointestinal problems and a low blood platelet count. Rituximab and liposomal doxorubicin are drugs given by a catheter into a vein. Interferon-alpha is given by injection into the skin. Those drugs are not experimental, but their use in Castleman s disease is experimental.

Some participants may be treated with a combination of chemotherapy followed by interferon-alpha. Interferon-alpha is infected into the skin by a needle. The natural form of interferon is produced by the body and helps to control viral infections. KSHV decreases the effect of the body s interferon, and the researchers want to see if giving higher doses of interferon will help to control KSHV infection.

A positron emission tomography (PET) scan, for research purposes only, may be done up to three times a year. A radioactive sugar molecule called fluorodeoxyglucose, or FDG, is used. It is believed that activated lymphocytes that may be found in participants disease might use more FDG because these cells burn more glucose fuel.

This study may or may not have a direct benefit for participants. However, detailed assessments made throughout the study may provide information to help the doctors treat KSHV-MCD better.



  • Multicentric Castleman's disease (MCD) is a rare but lethal Kaposi's sarcoma-associated herpesvirus (KSHV) associated lymphoproliferative disorder with a median survival of 2 years. It occurs more often in HIV-infected individuals than those without HIV infection. The poor prognosis is not fully explained by the underlying HIV, as the HIV-negative cases appear to have no survival advantage over the HIV-positive cohort. The disease has no defined standard treatment and has not been prospectively studied in a comprehensive manner.
  • KSHV-MCD may provide a model for the development of targeted oncolytic virotherapy or other pathogenesis-based approaches to viral-associated malignancies. In KSHV-MCD, viral encoded tyrosine kinase genes appear to be possible targets to exploit in a virotherapy approach. Specific viral encoded genes appear to convert zidovudine and ganciclovir (or valganciclovir) into toxic phosphorylated moieties within the KSHV-infected tumor cells, to specifically target the KSHV-infected cells thus leading to specific cell death. If successful, this could have direct therapeutic benefit to participants and also provide a model for further development of this approach in other tumors.


-To study and describe the natural history of KSHV-MCD.


  • Age greater than or equal to 18 years
  • Biopsy proven KSHV-associated MCD


  • Natural History study
  • Inclusion of treatment as needed, with guidelines for preliminary investigation of a variety of specific treatments of interest
  • High-dose zidovudine and ganciclovir
  • High-dose zidovudine and ganciclovir and bortezomib
  • Sirolimus
  • Rituximab with liposomal doxorubicin followed by interferon-alpha
  • Rituximab with EPOCH chemotherapy

Condition HIV, HIV positive, HIV infection, Cancer, AIDS Vaccines, Kaposi's Sarcoma, Lymphoproliferative Disorder, human herpesvirus 8, Cancer/Tumors, Ewing's Family Tumors, Cancer (Pediatric), HIV (Pediatric), HIV Infections, Neoplasms, Lymphoproliferative disorders, primary cancer, primary malignant neoplasm, lymphoproliferative disease, malignancy, cancers, malignancies, malignant tumor, malignant tumors, human immunodeficiency virus, hiv disease, HIV Vaccine, hiv vaccines, kaposi sarcoma
Treatment Rituximab, cyclophosphamide, etoposide, prednisone, vincristine, doxorubicin, Bortezomib, Interferon-alpha, Zidovudine, Zidovudine, Liposomal Doxorubicin, Liposomal Doxorubicin, Valganciclovir, Filgrastim (G-CSF), Sirolimus, Sirolimus, Observation only
Clinical Study IdentifierNCT00092222
SponsorNational Cancer Institute (NCI)
Last Modified on15 September 2021


Yes No Not Sure

Inclusion Criteria

Age greater than or equal to 18 years
Biopsy proven KSHV-associated MCD, confirmed in the Laboratory of Pathology
Willing to give informed consent

Exclusion Criteria

Any abnormality that would be scored as NCI CTC Grade IV toxicity that is
unrelated to HIV, its treatment, or to MCD that would preclude protocol
treatment and/or observation only
Presence of another malignancy requiring current treatment that would preclude
the use of all of the study treatments or the ability to monitor the natural
history of MCD untreated
Pregnant women are excluded from this study as certain of the study agents
have the potential for teratogenic effects
Any condition or set of circumstances that in the opinion of the investigators
would make participation in this study unsafe or otherwise inappropriate for a
given individual
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note